Patoulias D, Muzurovic E, Maggio V, Rizzo M, et al. Extending beyond established cardiometabolic benefits of empagliflozin in type 2 diabetes: the evolving paradigm of glycemic variability. J Diabetes Complications 2026 Feb 3:109276. doi: 10.1016/j.jdiacomp.2026.109276.
PMID: 41651687